CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data from the MoveDMD® trial of edasalonexent (CAT-1004) at the New Directions in Biology and Disease of Skeletal Muscle Conference, the 2018 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference and the 15th International Congress on Neuromuscular Diseases.
New Directions in Biology and Disease of Skeletal Muscle Conference to
be held June 25 – June 28, 2018 in New Orleans, LA, at The Westin New
Orleans Canal Place.
- Andrew Nichols, Ph.D., Chief Scientific Officer of Catabasis, will give an oral presentation titled “Edasalonexent, an NF-kB Inhibitor in Development as a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy” on Monday, June 25, 2018, from 3:10pm – 3:40pm ET in the Grand Ballroom on the 12th floor.
2018 PPMD Annual Connect Conference to be held June 28 – June 30, 2018
in Scottsdale, AZ, at The Phoenician.
- Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis, will present “MoveDMD: Phase 2 Trial of Edasalonexent, an NF-κB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy” during the poster session on Thursday, June 28, 2018, at 6:30pm MST and an oral presentation on Friday, June 29, 2018, from 2:20pm-2:40pm MST.
15th International Congress on Neuromuscular Diseases to be
held July 6 – July 10, 2018 in Vienna, Austria, at the Hilton Vienna
- Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis, will present “Rationale for Edasalonexent Dose Schedule in Phase 2 of the MoveDMD Trial” during the poster session on Saturday, July 7, 2018, from 17:15 – 18:30 CEST in the Exhibit Hall.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule that is being developed as a potential disease-modifying therapy for all patients affected by DMD, regardless of their underlying mutation. Edasalonexent inhibits NF-kB, a protein that is activated in DMD and drives inflammation, fibrosis and muscle degeneration and suppresses muscle regeneration. Edasalonexent continues to be dosed in an open-label extension of the MoveDMD Phase 2 clinical trial, and Catabasis is preparing for a single global Phase 3 trial to evaluate the efficacy and safety of edasalonexent for registration purposes, dependent on raising capital. The FDA has granted orphan drug, fast track and rare pediatric disease designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. For a summary of clinical results reported to-date, please visit www.catabasis.com.
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Edasalonexent was designed using our SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform that enables us to engineer molecules that simultaneously modulate multiple targets in a disease. For more information on edasalonexent or our drug discovery platform, please visit www.catabasis.com.